Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate
Generic Name: levonorgestrel and ethinyl estradiol and ferrous fumarate
Brand Names:
Joyeaux
11 DESCRIPTION Joyeaux (levonorgestrel and ethinyl estradiol tablets, USP, and ferrous fumarate tablets) provides an oral contraceptive regimen consisting of 21 white active tablets and 7 brown inactive tablets.
Overview
11 DESCRIPTION Joyeaux (levonorgestrel and ethinyl estradiol tablets, USP, and ferrous fumarate tablets) provides an oral contraceptive regimen consisting of 21 white active tablets and 7 brown inactive tablets.
Uses
1 INDICATIONS AND USAGE Joyeaux is indicated for use by females of reproductive potential to prevent pregnancy. Joyeaux is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )
Dosage
2 DOSAGE AND ADMINISTRATION • Take one tablet by mouth at the same time every day. ( 2.1 ) • Take tablets in the order directed on the blister pack. ( 2.1 ) 2.1 How to Start Joyeaux Joyeaux is dispensed in a blister card [see How Supplied/Storage and Handling ( 16 )] . Joyeaux may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.
Side Effects
6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: • Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Vascular events [see Warnings and Precautions ( 5.1 )] • Liver disease [see Warnings and Precautions ( 5.2 )] Adverse reactions commonly reported by COC users are: • Irregular uterine bleeding • Nausea • Breast tenderness • Headache Common adverse reactions (≥2% of women): headache (14%), metrorrhagia (8%), dysmenorrhea and nausea (7% each), abdominal pain and breast pain (4% each), emotional lability and acne (3% each), and depression, amenorrhea, and vaginal moniliasis (2% each) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiromed, LLC at 844-XIROMED (844-94...
Interactions
7 DRUG INTERACTIONS Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding.
Warnings
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 )] . 5 WARNINGS AND PRECAUTIONS • Thrombotic Disorders and Other Vascular Problems : Stop Joyeaux if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) • Liver disease : Discontinue Joyeaux if jaundice occurs ( 5.2 ) • High blood pressure: If used in women with well-controlled hypertension, monitor blood pressure and stop Joyeaux if blood pressure rises significantly. ( 5.4 ) • Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Joyeaux. 4 CONTRAINDICATIONS Joyeaux is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic disease.
Pregnancy
8.1 Pregnancy Risk Summary Joyeaux is contraindicated in pregnancy because there is no reason to use combined hormonal contraceptives (CHCs) in pregnancy. Discontinue Joyeaux if pregnancy occurs. Based on epidemiologic studies and meta-analyses, there is little or no increased risk of birth defects in the children of females who inadvertently use COCs during early pregnancy (See Data ) . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Joyeaux is available in a blister pack containing 28 tablets arranged in 3 rows of 7 active tablets and 1 row of inactive tablets, as follows: • 21 active tablets: white, round tablet debossed with “SZ” on one side and "L2" on the other side; each tablet containing levonorgestrel 0.10 mg and ethinyl estradiol 0.02 mg • 7 inactive tablets: brow...
Frequently Asked Questions
What is Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate used for?▼
1 INDICATIONS AND USAGE Joyeaux is indicated for use by females of reproductive potential to prevent pregnancy. Joyeaux is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )
What are the side effects of Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate?▼
6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: • Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Vascular events [see Warnings and Precautions ( 5.1 )] • Liver disease [see Warnings and Precautions ( 5.2 )] Adverse reactions commonly reported by COC users are: • Irregular uterine bleeding • Nausea • Breast tenderness • Headache Common adverse reactions (≥2% of women): headache (14%), metrorrhagia (8%), dysmenorrhea and nausea (7% each), abdominal pain and breast pain (4% each), emotional lability and acne (3% each), and depression, amenorrhea, and vaginal moniliasis (2% each) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiromed, LLC at 844-XIROMED (844-94...
Can I take Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate during pregnancy?▼
8.1 Pregnancy Risk Summary Joyeaux is contraindicated in pregnancy because there is no reason to use combined hormonal contraceptives (CHCs) in pregnancy. Discontinue Joyeaux if pregnancy occurs. Based on epidemiologic studies and meta-analyses, there is little or no increased risk of birth defects in the children of females who inadvertently use COCs during early pregnancy (See Data ) . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.
What are the important warnings for Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate?▼
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 )] . 5 WARNINGS AND PRECAUTIONS • Thrombotic Disorders and Other Vascular Problems : Stop Joyeaux if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) • Liver disease : Discontinue Joyeaux if jaundice occurs ( 5.2 ) • High blood pressure: If used in women with well-controlled hypertension, monitor blood pressure and stop Joyeaux if blood pressure rises significantly. ( 5.4 ) • Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Joyeaux. 4 CONTRAINDICATIONS Joyeaux is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic disease.
Related Medications
Ramelteon
ramelteon
Melatonin Receptor Agonist [EPC]
11 DESCRIPTION Ramelteon is an orally active hypnotic chemically designated as ( S )- N -[2-(1,6,7,8-tetrahydro-2 H -indeno-[5,4- b ]furan-8-yl)ethyl]propionamide and containing one chiral center. The compound is produced as the ( S )-enantiomer, with an empirical formula of C 16 H 21 NO 2 , molecular weight of 259.34, and the following chemical structure: Ramelteon is freely soluble in organic solvents, such as methanol, ethanol, and dimethyl sulfoxide; soluble in 1-octanol and acetonitrile; an
Mifepristone
mifepristone
Progestin Antagonist [EPC]
11 DESCRIPTION Mifepristone tablets each contain 200 mg of mifepristone, a synthetic steroid with antiprogestational effects. The tablets are light yellow coloured, round, biconvex, debossed with “CC12” on one side, plain on other side and free from physical defects and are intended for oral administration only. The tablets include the inactive ingredients colloidal silicon dioxide, maize starch, povidone, microcrystalline cellulose, and magnesium stearate.
Calendula Officinalis, Phytolacca Decandra, Bryonia Dioica, Balsamum Peruvianum, Dulcamara
calendula officinalis, phytolacca decandra, bryonia dioica, balsamum peruvianum, dulcamara
Standardized Chemical Allergen [EPC]
Uses For the temporary relief of symptoms associated with minor skin irritations.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.